Volume 20, Number 7—July 2014
Research
Changes in Capsule and Drug Resistance of Pneumococci after Introduction of PCV7, Japan, 2010–2013
Naoko Chiba, Miyuki Morozumi, Michi Shouji, Takeaki Wajima, Satoshi Iwata, Kimiko Ubukata
, and the Invasive Pneumococcal Diseases Surveillance Study Group
, and the Invasive Pneumococcal Diseases Surveillance Study Group
Table 3
Pneumococcal vaccination history and age for 156 children with invasive pneumococcal disease, Japan, 2012*
| No. vaccine doses administered | <6 mo | 7–11 mo | 1 y | 2 y | 3 y | 4 y | 5–9 y | >10 y | Total no. (%) |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7 [3] | 15 [8] | 4 [1] | 5 [2] | 8 [3] | 4 [1] | 5 [3] | 47 (30.1) | |
| 1 | 1 | 5 | 3 | 1 | 10 (6.4) | ||||
| 2 | 3 | 4 [1] | 1 | 2 | 1 | 11 (7.1) | |||
| 3 | 2 | 13 | 24 | 6 | 45 (28.8) | ||||
| Booster | 16 | 5 | 21 (13.5) | ||||||
| Unknown |
1 |
2 |
11 |
3 |
2 |
1 [1] |
1 |
22 (14.1) |
|
| Total |
6 |
22 |
71 |
19 |
14 |
12 |
6 |
6 |
156 (100.0) |
| *Numbers in brackets indicate infections with a vaccine serotype. | |||||||||
Page created: June 17, 2014
Page updated: June 17, 2014
Page reviewed: June 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.